共 50 条
- [1] The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk MyelofibrosisCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E463 - E466Tremblay, DouglasCavalli, LaraSy, OumarRose, ShelonitdaMascarenhas, John
- [2] Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA TrialBLOOD, 2020, 136Pardanani, AnimeshTefferi, AyalewMasszi, TamasMishchenko, ElenaDrummond, Mark W.Jourdan, EricVannucchi, Alessandro M.Jurgutis, MindaugasRibrag, VincentRambaldi, AlessandroKoh, Liang PiuRose, ShelonitdaZhang, JunHarrison, Claire
- [3] Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet countsBRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 317 - 327Harrison, Claire N.Schaap, NicolaasVannucchi, Alessandro M.Kiladjian, Jean-JacquesPassamonti, FrancescoZweegman, SonjaTalpaz, MosheVerstovsek, SrdanRose, ShelonitdaZhang, JunSy, OumarMesa, Ruben A.
- [4] Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM TrialBLOOD, 2021, 138Gupta, VikasYacoub, AbdulraheemVerstovsek, SrdanMesa, Ruben A.Harrison, Claire N.Barosi, GiovanniKiladjian, Jean-JacquesDeeg, H. JoachimFazal, SalmanFoltz, LyndaMattison, Ryan J.Miller, Carole B.Parameswaran, VinodGharpure, VishwanathHernandez, ChristopherWang, TianhuaTalpaz, Moshe
- [5] Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with RuxolitinibBLOOD, 2019, 134Harrison, Claire N.Schaap, NicolaasVannucchi, Alessandro M.Kiladjian, Jean-JacquesJourdan, EricSilver, Richard T.Schouten, Harry C.Passamonti, FrancescoZweegman, SonjaTalpaz, MosheVerstovsek, SrdanRose, ShelonitdaTang, DerekHu, AngelaGuo, ShienLiao, WeiqinBrownstein, CarrieMesa, Ruben A.
- [6] Early onset of spleen and symptom responses with fedratinib (FEDR) in patients with intermediate (Int)- or high-risk (HR) myelofibrosis (MF)ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 83 - 83Platzbecker, U.Passamonti, F.Reiter, A.Gisslinger, H.Doehner, K.Heidel, F.Niederwieser, D.Wolf, D.Jourdan, E.Harrison, C.Mesa, R.Devos, T.Cervantes, F.Rose, S.Zhang, J.Vannucchi, A.
- [7] Fedratinib Approved for High-Risk or Intermediate-2-Risk MyelofibrosisCLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 610 - 610Schuyler, Devon
- [8] Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinibEXPERT REVIEW OF HEMATOLOGY, 2022, 15 (07) : 583 - 595Saha, ChandanHarrison, Claire
- [9] The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase OAK) inhibitor: A phase 2, randomized study.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Tefferi, AyalewGangat, NaseemaNiederwieser, DietgerVan Droogenbroeck, JanBaer, Maria R.Kiladjian, Jean-JacquesHoffman, RonaldFinazzi, GuidoCervantes, FranciscoGotlib, Jason R.Sirhan, ShireenApperley, JaneLanglois, AngeliqueWan, YingSherman, Laurie JillDougherty, SouriaFeller, FayeOdenike, Olatoyosi
- [10] Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosisJournal of Translational Medicine, 13Catriona JamiesonRobert HasserjianJason GotlibJorge CortesRichard StoneMoshe TalpazJürgen ThieleScott RodigOlga Pozdnyakova